cudc-101

CUDC-101 is a multi-targeted small molecule inhibitor developed as an antineoplastic agent. It simultaneously inhibits three key targets involved in cancer progression: histone deacetylases (HDACs), epidermal growth factor receptor (EGFR/ErbB1), and human epidermal growth factor receptor 2 (HER2/ErbB2). By blocking these pathways, CUDC-101 disrupts oncogenic signaling, induces apoptosis, and suppresses tumor cell proliferation. The drug was primarily investigated for the treatment of various solid tumors including head and neck cancer, breast cancer, gastric cancer, liver cancer, non-small cell lung cancer (NSCLC), and other advanced or refractory cancers. Clinical studies demonstrated that CUDC-101 could inhibit its intended targets in patients and showed preliminary evidence of antitumor activity with manageable toxicity profiles[2][4][5][6][10].